Perrigo's OTC Priority Shows In Launch Of Imodium Multi-Symptom Equivalent
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Perrigo is launching generic of J&J’s OTC Imodium Multi-Symptom Relief product for diarrhea and gas. An analyst estimates the product could generate $15m in annualized sales.
You may also be interested in...
Perrigo's OTC Core Could Expand To Include National Brands
Submitting an OTC switch of Nasonex would be a first for Perrigo, as would marketing a national brand OTC if the switch is approved. In tandem with announcing divesture of Perrigo's Rx business, CEO Uwe Rohrhoff says marketing national brands in some OTC categories fits in the company's "value-creation road map."
Smaller OTC Loperamide Packages Wait As Retailers Limit Purchase Amounts
Commissioner Scott Gottlieb updates US FDA's initiative to prevent potentially fatal abuse of OTC loperamide, noting that online and conventional retailers are limiting product purchases while the agency continues evaluating the appropriate number of doses per package.
Amazon OTCs Likely A Worry For Retailers, A Remedy For Perrigo
Amazon introduced Basic Care line of cough, cold, allergy and digestive treatment OTCs developed in a partnership with Perrigo. The range could be a major threat to store brand and private label OTCs, though success may depend on whether consumers wait for Amazon deliveries or shop at stores.